Abstract
Cancer is a serious disease characterized by the uncontrolled growth division of cells, and nowadays it remains a significant challenge for the medical field. Malaria is an infectious disease in the similar situation to cancer. Almost 40% people in the world live in areas with malaria risk and each year there are about 2 to 3 million people dying from malaria. Farnesyltransferase (FTase) that belongs to isoprenyltransferase family can catalyze the initial step of Ras-processing and is identified as a promising target for the treatment of cancer and malaria. During the past decade years, a large number of FTase inhibitors with anticancer or antimalarial activity have been reported and some of them are undergoing clinical development. This review mainly introduces the FTase inhibitors as anticancer and antimalarial agents, with focus on their enzyme inhibitory activity, stability and enzyme selectivity, etc. In particular, the promising new FTase inhibitors among them will be discussed in detail and the inspirations for their design will be highlighted.
Keywords: Anticancer, antimalaria, farnesyltransferase, FTase inhibitors, FTase inhibitory activity, selectivity.
Mini-Reviews in Medicinal Chemistry
Title:The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents
Volume: 15 Issue: 10
Author(s): Yan Shen, Shengsheng Qiang and Shutao Ma
Affiliation:
Keywords: Anticancer, antimalaria, farnesyltransferase, FTase inhibitors, FTase inhibitory activity, selectivity.
Abstract: Cancer is a serious disease characterized by the uncontrolled growth division of cells, and nowadays it remains a significant challenge for the medical field. Malaria is an infectious disease in the similar situation to cancer. Almost 40% people in the world live in areas with malaria risk and each year there are about 2 to 3 million people dying from malaria. Farnesyltransferase (FTase) that belongs to isoprenyltransferase family can catalyze the initial step of Ras-processing and is identified as a promising target for the treatment of cancer and malaria. During the past decade years, a large number of FTase inhibitors with anticancer or antimalarial activity have been reported and some of them are undergoing clinical development. This review mainly introduces the FTase inhibitors as anticancer and antimalarial agents, with focus on their enzyme inhibitory activity, stability and enzyme selectivity, etc. In particular, the promising new FTase inhibitors among them will be discussed in detail and the inspirations for their design will be highlighted.
Export Options
About this article
Cite this article as:
Shen Yan, Qiang Shengsheng and Ma Shutao, The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents, Mini-Reviews in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/1389557515666150511152433
DOI https://dx.doi.org/10.2174/1389557515666150511152433 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice
Current Pharmaceutical Biotechnology Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals
Anti-Cancer Agents in Medicinal Chemistry Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Mass Spectrometry Based Proteomics for Interrogating the Histone Code
Current Proteomics Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery Self-Organizing Map (SOM) and Support Vector Machine (SVM) Models for the Prediction of Human Epidermal Growth Factor Receptor (EGFR/ ErbB-1) Inhibitors
Combinatorial Chemistry & High Throughput Screening Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling
Current Neurovascular Research ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Recent Patents on Liposomal-Based Chemotherapeutics with a Triggered Release Mechanism
Recent Patents on Nanomedicine CSPG4 in Cancer: Multiple Roles
Current Molecular Medicine microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design